UCB's Global Corporate Website

Exploring the future of dermatology at AAD 2023

Posted by
Eimear O'Brien, Global Communications & Company Reputation

The American Academy of Dermatology (AAD) Annual Meeting takes place this week in New Orleans, Louisiana, U.S., 17-21 March. We spoke with Braulio Gomez, U.S. Medical, UCB and Owen Davies, Global Medical, UCB to find out more. 

What can you tell us about AAD 2023? 
Braulio Gomez: AAD 2023 is among the largest and most significant yearly meetings in the field of dermatology. Each year, this meeting brings together the community for a comprehensive learning experience, offering scientific sessions that comprise symposia, forums and interactive workshops. Hosted in New Orleans this year, it is anticipated that the meeting will attract thousands of medical professionals from all over the world. The event provides an opportunity for distinguished experts, clinicians, and scientists to share their expertise, best practices, and insights in the field of dermatology. As a long-standing participant of AAD, UCB is committed to advancing research in and to providing solutions that meet the needs of patients across a range of dermatological conditions. We look forward to connecting with the community this week to share and discuss the latest research, collaborate with peers, and explore the future of dermatology.

Can you share more about UCB’s commitment in the area of dermatology?
Owen Davies:
UCB is committed to improving the lives of individuals affected by immune-mediated inflammatory diseases, and we are passionate about creating a world where these diseases no longer impose a burden on patients. We believe that collaborating closely with the community is crucial to achieving this goal, as it leads to a deeper understanding of patients’ needs, advances in clinical knowledge and scientific understanding. Our Patient Value Strategy places the patient and their experiences at the forefront of everything we do. Through our dermatology partnerships we are able to build strong connections with both the patient and scientific communities. This close collaboration enables us to gain a deep scientific understanding of dermatological conditions and helps us to enhance standards of care and demonstrate our dedication to improving patient outcomes.

Can you tell us about UCB’s scientific presence at AAD 2023?
Owen Davies:
This year, we are excited to share our latest research in moderate to severe plaque psoriasis, active psoriatic arthritis, and moderate to severe hidradenitis suppurativa. We are thrilled to be presenting eight abstracts, which have been accepted as seven posters and one oral platform presentation. These abstracts represent the culmination of our commitment to advancing dermatology research and improving the standard of care for individuals affected by these conditions.

What can healthcare professionals expect to experience at the medical section of UCB’s booth?
Braulio Gomez:
At the medical section of the booth, delegates can look forward to an interactive and immersive experience with the opportunity to learn more about hidradenitis suppurativa, psoriatic arthritis and psoriasis. If you are a healthcare professional attending AAD 2023, we look forward to welcoming you to our booth, where you will have the opportunity to meet members of our UCB team, discuss the latest research, and explore further innovative approaches to help address patients’ needs.

What are your hopes for the future of dermatology?
Braulio Gomez and Owen Davies:
Scientific understanding of many inflammatory dermatological diseases is advancing at an incredible rate – but there’s still much to be done to help people living with these debilitating diseases live to the fullest. At UCB, we share a vision of a future where innovative science and technology drive progress in disease management. With increased understanding of conditions such as hidradenitis suppurativa, psoriasis, and psoriatic arthritis, we believe that pioneering new approaches to disease management will emerge, providing hope for patients and healthcare providers alike.
Collaboration is also key to growing our collective, scientific understanding of dermatological conditions and we always look for ways to work closely with the most passionate partners as we strive to improve every stage of the patient journey. We look forward to continuing our close collaborations with all stakeholders and we believe that our shared commitment to advancing dermatology research will result in a brighter future for patients and healthcare providers.

Stay up to date with UCB news from the 2023 AAD Annual Meeting by following us on our social media channels, including Twitter and LinkedIn.

Leave a Comment

By submitting your personal data, you agree with UCB's Data Privacy Policy. Furthermore, for more information on the terms of use of this website please visit our Legal Notice, accessible here.


Enter the characters shown in the image.